Value of the lung immune prognostic index in patients with advanced small cell lung cancer treated with programmed death-ligand 1 and programmed death-1 inhibitors in the Chinese alpine region

PurposeTo assess the potential added value of the lung immune prognostic index (LIPI) in patients with small cell lung cancer (SCLC), treated with programmed death-ligand 1 (PD-L1)/programmed death-1 (PD-1) inhibitors, who lived in the Chinese alpine region.Methods120 SCLC patients treated with PD-L...

Descripció completa

Dades bibliogràfiques

Autors principals:	Meiling Zhang, Jingwei Hao, Yunjiao Wu, Ziyi Gao, Meng Wang
Format:	Artigo
Idioma:	Inglês
Publicat:	Frontiers Media S.A. 2024-09-01
Col·lecció:	Frontiers in Oncology
Matèries:	lung immune prognostic index (LIPI) small cell lung cancer (SCLC) programmed death-ligand 1 (PD-L1) programmed death-1 (PD-1) immune-related adverse events (irAEs) prognostic factor
Accés en línia:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1411548/full
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!